Form 4: Harte Hanks Director Receives RSU Grant

Harte Hanks Director Genevieve Claire Combes reported the acquisition of 27,861 restricted stock units and disclosed existing deferred RSU holdings.

Summary

• Genevieve Claire Combes, a Director of Harte Hanks Inc. (HHS), reported changes in her beneficial ownership.
• On December 9, 2025, she was granted 27,861 Restricted Stock Units (RSUs) at a price of $3.23 per share.
• These newly granted RSUs are scheduled to vest 100% on December 9, 2026, which is the first anniversary of the grant date.
• Combes also holds 12,048 RSU shares granted on May 23, 2024, which vested on May 23, 2025, but she chose to defer their receipt.
• Additionally, she holds 16,216 RSU shares granted on August 17, 2023, which vested on August 17, 2024, with receipt also deferred.
• The filing indicates a direct beneficial ownership of 26,283 shares of Common Stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive, reflecting standard director compensation and a director's decision to defer vested shares, which can be interpreted as confidence in the company's future. No significant negative or overwhelmingly positive news is present.

Positives

• The grant of 27,861 RSUs to a director aligns her interests with shareholders, incentivizing long-term performance.
• The deferral of vested RSU shares (12,048 and 16,216 shares) by the director suggests confidence in the company's future stock performance.

Future Outlook

The filing indicates future vesting dates for RSU grants, specifically December 9, 2026, for the most recent grant. The deferral of receipt for previously vested RSUs suggests a long-term perspective from the director.

Industry Context

This Form 4 filing details routine equity compensation for a director, which is a standard practice across industries to align management and director interests with shareholder value. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation for directors is a common practice in publicly traded companies, comparable to practices at peers in the marketing services or data analytics sectors.
• The deferral of vested shares is also a common strategy for executives and directors, often for tax planning purposes or to signal long-term commitment, similar to practices observed at companies like Acxiom or Epsilon.

Corporate Governance

Related Party Transactions

• The RSU grant to a director is a related party transaction, but it is a standard form of compensation and disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with long-term shareholder value. The deferral of vested shares may signal director confidence.
• Employees: No direct impact on general employees is indicated.
• Management: The director's compensation structure is detailed.

Next Steps

• The 27,861 RSU shares are expected to vest on December 9, 2026.
• The deferred 12,048 RSU shares and 16,216 RSU shares will be received by the participant at a later, unspecified date.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to director compensation and existing equity holdings. While the RSU grant and deferral of vested shares can be seen as a positive signal of director alignment and confidence, it does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Harte Hanks, HHS, Form 4, SEC filing, Restricted Stock Units, RSU grant, insider transaction, beneficial ownership, director compensation, equity compensation, Rule 10b5-1